Annovis Bio, Inc. Stock News

EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.

Investor confusion surrounding Annovis's interim analysis of its Phase 3 Parkinson's (PD) study highlights the need, in my view, for improved PR processes at Annovis. The company will have ~9 months t

Annovis Bio, Inc. (ANVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Lead asset buntanetap represents a differentiated, potentially disease-modifying mechanism of action in neurodegenerative diseases. Interim Phase 3 Parkinson's data to be presented today (3/30/23) at

Annovis Bio, Inc. (ANVS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro

COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.

Here is how Annovis Bio, Inc. (ANVS) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.

BERWYN, Pa. , Oct. 20, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that

Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).

Green light received from the FDA to initiate a phase 3 study using buntanetap for the treatment of early-stage Parkinson's Disease patients. The global Parkinson's Disease market is expected to reach

Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.

Maria Maccecchini, Ph.D., Founder, President, and CEO, will be participating on a panel discussing the Systems Biology of Alzheimer's Disease moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctô

Annovis Bio Inc (NYSE: ANVS) received notice from the FDA that the Phase 3 clinical study with buntanetap in early Parkinson's patients may proceed.  The FDA accepted the final protocol and the cl

Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, tod

Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's Disease (PD) as an offshoot of the Comp